Patent application number | Description | Published |
20080268473 | Adamts-7 as a Biomarker for Cancers of Epithelial Origin - ADAMTS-7 expression and activity are up regulated in patients that have cancers of epithelial origin. Accordingly, the present invention is directed to methods diagnosis of cancers of epithelial origin (e.g. breast cancer, prostate cancer, bladder cancer, brain cancer and hepatic cancer). In particular, the presence of ADAMTS-7 in a biological sample is indicative of cancer of epithelial origin. Thus, measuring the level of ADAMTS-7 in biological samples (e.g. urine or blood) provides a quick, easy, and safe screen that can be used to diagnose cancer in a patient. | 10-30-2008 |
20080286811 | Cyr61 as a Biomarker for Diagnosis and Prognosis of Cancers of Epithelial Origin - Urinary Cyr61 protein levels are up regulated in patients that have cancers of epithelial origin, i.e. breast cancer and ovarian cancer. Accordingly, the present invention is directed to methods for prognostic evaluation, and diagnosis of cancers of epithelial origin. Further, the amount of Cyr61 protein detected in a urine sample correlates with disease status such that Cyr61 levels can be used to predict the presence of, as well as the metastatic potential of cancer. Thus, measuring the level of Cyr61 in urine provides a quick, easy, and safe screen that can be used to both diagnose and prognose cancer in a patient. | 11-20-2008 |
20090156491 | METHODS OF INHIBITING ANGIOGENESIS WITH FRAGMENTS AND HOMOLOGS OF TROPONIN SUBUNIT I - The present invention relates to methods of inhibiting angiogenesis associated with a disease or disorder with peptides homolgous to amino acid residues 130-137 or 132-139 of human troponin subunit I. | 06-18-2009 |
20090203590 | METHOD FOR THE INHIBITION OF ANGIOGENESIS - The present invention is based on the discovery that Matrilin-1 has antiangiogenic and anticancer properties. The invention is directed to a method of treating a disease that responds to an inhibition of angiogenesis. Additionally, the invention can be applied to those at risk for developing a disease that responds to an inhibition of angiogenesis. The methods comprise administering to a mammal an effective angiogenesis-inhibiting amount of an Matrilin-1 consisting of Matrilin-1, Matrilin-1 fragment, analog, or derivative that is administered in a composition substantially free of other cartilage proteins. | 08-13-2009 |
20090209497 | METHOD OF TREATING LYMPHANGIOLEIOMYOMATOSIS (LAM) - The invention provides a method for the treatment of Lymphangioleiomyomatosis (LAM) in the human subject in need thereof. The method comprises administering to the subject an effective amount of doxycycline or a salt thereof. The invention further provides a method for monitoring the efficacy of treatment. Treatment efficacy is monitored by measuring MMP levels. Reduction in MMP levels indicates that the treatment is effective. | 08-20-2009 |
20090221533 | METHOD OF TREATING FATTY LIVER DISEASE - The present invention relates to a method for treating a fatty liver disease or disorder in a patient in need thereof. The method comprises administering at least one matrix metalloproteinase (“MMP”) inhibitor to the patient. Fatty liver disease or disorders include, for example, NAFLD, NASH, ALD, fatty liver associated with chronic hepatitis infection, TPN, steroid treatment, tamoxifen treatment, gastrointestional operations, diabetes and Reye's Syndrome. The method is particularly useful when the fatty liver disease is associated with TPN and the patient is an infant or when the patient is obese. MMP inhibitors useful in the present invention include, for example, Marimastat, tetracyclines, Prinomastat, Batimastat, BAY 12-9566, AG3340, BMS-275291, Neovastat, BB-3644, KB-R7785, TIMP1, TIMP2, doxycycline, minocycline, RS-130,830; CGS 27023A, Solimastat, Ro 32-3555, BMS-272591, and D2163. Marimastat is a preferred MMP inhibitor. | 09-03-2009 |
20100209944 | ADAMTS-7 AS A BIOMARKER FOR CANCERS OF EPITHELIAL ORIGIN - ADAMTS-7 expression and activity are up regulated in patients that have cancers of epithelial origin. Accordingly, the present invention is directed to methods diagnosis of cancers of epithelial origin (e.g. breast cancer, prostate cancer, bladder cancer, brain cancer and hepatic cancer). In particular, the presence of ADAMTS-7 in a biological sample is indicative of cancer of epithelial origin. Thus, measuring the level of ADAMTS-7 in biological samples (e.g. urine or blood) provides a quick, easy, and safe screen that can be used to diagnose cancer in a patient. | 08-19-2010 |
20100284992 | Phospholipase C and Method of Use - The present invention provides a method for reducing angiogenesis using a phospholipase C. | 11-11-2010 |
20110081650 | FREE NGAL AS A BIOMARKER FOR CANCER - Uncomplexed neutrophil gelatinase associated lipocalin (NGAL) is present at increased levels in individuals with atypical ductal hyperplasia (ADH), a major risk factor for future breast cancer development; in individuals that have ovarian cancer; and in individuals that have breast cancer, both invasive and noninvasive. Accordingly, the present invention is directed to measuring uncomplexed NGAL levels in urine as a primary screen to determine if an individual is either at risk of developing, or has developed cancer, e.g., cancer of epithelial origin including breast and ovarian cancer. | 04-07-2011 |
20110189700 | CYR61 AS A BIOMARKER FOR DIAGNOSIS AND PROGNOSIS OF CANCERS OF EPITHELIAL ORIGIN - Urinary Cyr61 protein levels are up regulated in patients that have cancers of epithelial origin, i.e. breast cancer and ovarian cancer. Accordingly, the present invention is directed to methods for prognostic evaluation, and diagnosis of cancers of epithelial origin. Further, the amount of Cyr61 protein detected in a urine sample correlates with disease status such that Cyr61 levels can be used to predict the presence of, as well as the metastatic potential of cancer. Thus, measuring the level of Cyr61 in urine provides a quick, easy, and safe screen that can be used to both diagnose and prognose cancer in a patient. | 08-04-2011 |
20140178893 | NON-INVASIVE ENZYME SCREEN FOR TISSUE REMODELLING-ASSOCIATED CONDITIONS - Methods and kits for diagnosing the presence of and prognosing the appearance of tissue remodelling-associated conditions, involving the presence of enzymes in a biological sample, are disclosed. In particular, the method pertains to diagnosing the presence of or prognosing appearance of cancer, metastatic cancer, and obstructive and degenerative conditions. | 06-26-2014 |
20140242616 | FREE NGAL AS A BIOMARKER FOR CANCER - Uncomplexed neutrophil gelatinase associated lipocalin (NGAL) is present at increased levels in individuals with atypical ductal hyperplasia (ADH), a major risk factor for future breast cancer development; in individuals that have ovarian cancer; and in individuals that have breast cancer, both invasive and noninvasive. Accordingly, the present invention is directed to measuring uncomplexed NGAL levels in urine as a primary screen to determine if an individual is either at risk of developing, or has developed cancer, e.g., cancer of epithelial origin including breast and ovarian cancer. | 08-28-2014 |
20140356882 | NON-INVASIVE ENZYME SCREEN FOR TISSUE REMODELLING-ASSOCIATED CONDITIONS - Methods and kits for diagnosing the presence of and prognosing the appearance of tissue remodelling-associated conditions, involving the presence of enzyme complexes in a biological sample, are disclosed. In particular, the method pertains to diagnosing the presence of or prognosing appearance of metastatic cancer by the identification of high molecular weight enzyme complexes comprising MMPs. | 12-04-2014 |
20150037814 | NON-INVASIVE ENZYME SCREEN FOR TISSUE REMODELLING-ASSOCIATED CONDITIONS - Methods and kits for diagnosing the presence of and prognosing the appearance of tissue remodelling-associated conditions, involving the presence of enzymes in a biological sample, are disclosed. In particular, the method pertains to diagnosing the presence of or prognosing appearance of cancer, metastatic cancer, and obstructive and degenerative conditions. | 02-05-2015 |